반응식
[Cl:1][C:2]1[CH:3]=[CH:4][N:5]=[C:6]2[C:10]=1[NH:9][CH:8]=[C:7]2[C:11](=[O:15])[C:12]([O-:14])=O.[K+].[C:17]([N:25]1[CH2:30][CH2:29][NH:28][C@H:27]([CH3:31])[CH2:26]1)(=[O:24])[C:18]1[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=1>>[C:17]([N:25]1[CH2:30][CH2:29][N:28]([C:12](=[O:14])[C:11]([C:7]2[C:6]3[C:10](=[C:2]([Cl:1])[CH:3]=[CH:4][N:5]=3)[NH:9][CH:8]=2)=[O:15])[C@H:27]([CH3:31])[CH2:26]1)(=[O:24])[C:18]1[CH:19]=[CH:20][CH:21]=[CH:22][CH:23]=1참가 물질
3
실험 절차
Precursor 5d, 1-benzoyl-3-(R)-methyl-4-[(7-chloro-4-azaindol-3-yl)-oxoacetyl]piperazine was prepared by the same method as Precursor 5a, starting from Potassium (7-chloro-4-azaindol-3-yl)-oxoacetate, Precursor 4e, and 1-benzoyl-3-(R)— methyl piperazine. MS m/z: (M+H)+ calcd for C21H20ClN4O3 411.12, found 411.04. HPLC retention time: 1.10 minutes (column A).
출처 및 근거
- ORD 기록
- ord-334d0f9ba7154efe8723fcc32141ea28
- 출처 데이터셋
- uspto-grants-2010_02
- 특허 번호
- US07662823B2
연결된 노트
불러오는 중…